H J Deeg
Overview
Explore the profile of H J Deeg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
424
Citations
5526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luque R, Osborn H, Leleu A, Palle E, Bonfanti A, Barragan O, et al.
Nature
. 2023 Nov;
623(7989):932-937.
PMID: 38030780
Planets with radii between that of the Earth and Neptune (hereafter referred to as 'sub-Neptunes') are found in close-in orbits around more than half of all Sun-like stars. However, their...
2.
Vaughn J, Anwer F, Deeg H
Vox Sang
. 2015 Jul;
110(1):5-11.
PMID: 26178735
Several lines of therapy have been established for patients with immune thrombocytopenia (ITP) and Evans syndrome. However, these therapies generally require prolonged administration, lead to profound immunosuppression and increased infectious...
3.
Deeg H
Bone Marrow Transplant
. 2015 Jun;
50(9):1145-9.
PMID: 26052908
The prevalence of diseases such as AML or myelodysplastic syndromes increases with the aging of the population. Only intensive chemotherapy or hematopoietic cell transplantation have curative potential. However, comorbid conditions...
4.
Deeg H, Sullivan K
Immunol Today
. 2014 Oct;
4(6):155-6.
PMID: 25289533
Since its first successful application less than 15 years ago, allogeneic marrow transplantation has been used with continuously improving results for the treatment of severe aplastic anemia, leukemia and congenital...
5.
Castilla-Llorente C, Martin P, McDonald G, Storer B, Appelbaum F, Deeg H, et al.
Bone Marrow Transplant
. 2014 Apr;
49(7):966-71.
PMID: 24777184
We hypothesized that clinical risk factors could be identified within 2 weeks of onset of severe (stage 3 or 4) acute gut GVHD for identifying a patient population with a...
6.
Li X, Marcondes A, Ragoczy T, Telling A, Deeg H
Blood Cancer J
. 2013 Apr;
3:e113.
PMID: 23624784
Engraftment of clonal hematopoietic precursor cells from patients with myelodysplastic syndrome (MDS) in immunodeficient mice has been difficult to achieve by intravenous (i.v.) injection. We used i.v. coadministration of the...
7.
Warren E, Deeg H
Tissue Antigens
. 2013 Mar;
81(4):183-93.
PMID: 23510414
The intrinsic anti-leukemic effect of allogeneic hematopoietic cell transplantation (HCT) is dependent on genetic disparity between donor and recipient, intimately associated with graft-versus-host disease (GVHD), and mediated by lymphocytes contained...
8.
Thakar M, Bonfim C, Sandmaier B, ODonnell P, Ribeiro L, Gooley T, et al.
Pediatr Hematol Oncol
. 2012 Jul;
29(6):568-78.
PMID: 22839094
Allogeneic hematopoietic cell transplantation (HCT) is the only known cure for patients with Fanconi anemia (FA) who develop aplasia or leukemia. However, transplant regimens typically contain high-dose alkylators, which are...
9.
Zimmerman Z, Scott B, Gopal A, Sandmaier B, Maloney D, Deeg H
Bone Marrow Transplant
. 2011 Sep;
47(6):804-9.
PMID: 21909142
Allogeneic hematopoietic cell transplantation (HCT) can be curative for both myelodysplastic syndromes (MDS) and lymphoid malignancies. Little is known about the efficacy of allogeneic HCT in patients in whom both...
10.
Deeg H
Can Fam Physician
. 2011 Jan;
34:2489-98.
PMID: 21253121
The author of this paper presents an overview of the current status of bone marrow transplantation, including indications, pre-transplant considerations, the transplant procedure, acute and delayed transplant-related problems, results currently...